Catalyst Pharmaceuticals (CPRX) Liabilities and Shareholders Equity (2010 - 2026)

Catalyst Pharmaceuticals has reported Liabilities and Shareholders Equity for 17 years, with the latest figure at $1.1 billion in Q1 2026.

• For the quarter ending Q1 2026, Liabilities and Shareholders Equity rose 26.27% year-over-year to $1.1 billion; the trailing twelve-month figure through Mar 2026 stood at $4.3 billion (up 32.0% YoY), and the FY2025 full-year result was $1.1 billion, up 29.66% from the prior year.
• Liabilities and Shareholders Equity for Q1 2026 stood at $1.1 billion, up from $1.1 billion in the prior quarter.
• The five-year high for Liabilities and Shareholders Equity was $1.1 billion in Q1 2026, with the low at $247.0 million in Q1 2022.
• Historically, Liabilities and Shareholders Equity has averaged $654.0 million across 5 years, with a median of $646.7 million in 2024.
• Annual changes were most pronounced in 2023 — Liabilities and Shareholders Equity rose 24.04% — and 2024, when it soared 86.83%.
• Catalyst Pharmaceuticals' Liabilities and Shareholders Equity stood at $375.6 million in 2022, then grew by 25.15% to $470.1 million in 2023, then soared by 81.11% to $851.4 million in 2024, then gained by 29.66% to $1.1 billion in 2025, then advanced by 3.95% to $1.1 billion in 2026.
• The last three Liabilities and Shareholders Equity figures came in at $1.1 billion (Q1 2026), $1.1 billion (Q4 2025), and $1.1 billion (Q3 2025), per Business Quant data.